Options Bears Eye Plummeting Biotech Stock

Biotech stock Travere Therapeutics Inc (NASDAQ:TVTX) is plummeting today, down 32.8% to trade at $22.92 at last glance, after news that the Food & Drug Administration (FDA) has new questions regarding its Filspari application, which could cause a potential delay for the serious kidney disease treatment. The market is brushing off the company's strong fourth-quarter sales, which closed out "an exceptional year of commercial execution with Filspari," per President and CEO Eric Dube, Ph. D.Should these losses ...